Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Q2 2024 Earnings Presentation
18 slides from Day One Biopharmaceuticals's earnings presentation, Jul 30, 2024
Slide 1: Second Quarter 2024 Financial Results and Corporate Progress
Second Quarter 2024 Financial Results and Corporate Progress July 2024 Click to add text Nasdaq: DAWN
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and unc
Slide 3: Agenda & Day One Participants
Agenda & Day One Participants Opening Remarks Jeremy Bender (Chief Executive Officer) OJEMDATM (tovorafenib) Commercial Performance Lauren Merendino (Chief Commercial Officer) Portfolio Expansion & Updates Sam Blackman (Co-Founder & Head of R&D) Second Quarter 2024 Financial Performance Charles York
Slide 4: Opening Remarks
Opening Remarks Jeremy Bender Chief Executive Officer
Slide 5: Executing On Our Priorities As A Commercial-Stage Company
Executing On Our Priorities As A Commercial-Stage Company 1 Represents cash, cash equivalents and short-term investments as of June 30, 2024. OJEMDA Launch Strong start with $8.2M in net product revenue in the initial 8 weeks on market Commercial Execution Strong cadence of new patient starts and ra
Slide 6: OJEMDA (tovorafenib) Commercial Performance
OJEMDATM (tovorafenib) Commercial Performance Lauren Merendino Chief Commercial Officer
Slide 7: Robust Q2 Performance Driven by Excellent Execution & Strong Patient Demand
Robust Q2 Performance Driven by Excellent Execution & Strong Patient Demand pLGG, pediatric low-grade glioma Q2 OJEMDA Net Revenue $8.2M ~75% Patient Demand ~25% Inventory Launch Execution Excellence Accelerated Customer Engagement Live engagements with >90% of ~200 target accounts $6.1M $2.1M Payer
Slide 8: Patient Demand Driven By Both EAP Transition Patients and New Patient Starts
Patient Demand Driven By Both EAP Transition Patients and New Patient Starts * Includes US patients on paid drug and commercial free drug programs. Does not include patients not yet transitioned from EAP. Rapid transition of patients on Early Access Program (EAP) to commercial drug Strong new patien
Slide 9: Coverage Approval Rates are High Across Commercial and Medicaid Payers
Despite Limited Published Coverage To Date, Coverage Approval Rates are High Across both Commercial and Medicaid Payers 59% Commercial Patients 38% Medicaid Patients Commercial Reported Coverage1 Percent of Covered Lives Medicaid Reported Coverage2 Percent of Covered Lives 1Breakaway Partners LLC –
Slide 10: Well-Positioned For Commercial Execution And Sustained Growth
Well-Positioned For Commercial Execution And Sustained Growth Continuing Launch Trajectory Increase breadth & depth of prescribers Establish OJEMDA in the 2nd line Solidify payer coverage policies
Slide 11: Portfolio Expansion and Updates
Portfolio Expansion and Updates Sam Blackman Co-Founder & Head of R&D
Slide 12: DAY301: Next Generation ADC Targeting PTK7
DAY301: Next Generation ADC Targeting PTK7 1 Cho BC, et al. Ann Oncol. (34; Suppl 2): S460-S461, 2023. PTK7: Clinically-Validated ADC Target DAY301: Potential First-in-Class Asset Substantial Development and Potential Commercial Opportunities for DAY301 Anti-tumor activity of anti-PTK7 ADC demonstra
Slide 13: DAY301: Potential First-In-Class Asset
DAY301: Potential First-In-Class Asset 1) Damelin M, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017. HNSTD, Highest Non-Severely Toxic Dose; P-gp, P-glycoprotein. DAY301 has been designed to maximize therape
Slide 14: DAY301-001: Initial Phase 1/2a Clinical Trial Design
DAY301-001: Initial Phase 1/2a Clinical Trial Design DL, Dose Level; RD, Recommended Dose; BOIN, Bayesian Optimal Interval; HNSCC, Head and Neck Squamous Cell Carcinoma; SCLC, Small Cell Lung Cancer; SCC, Squamous-Cell Carcinoma; NSCLC, Non-Small Cell Lung Cancer Phase 1a: Monotherapy Dose Escalatio
Slide 15: Our Pipeline
pLGG, pediatric low-grade glioma. 1 OJEMDA has received accelerated approval by the U.S. Food and Drug Administration. 2 FIREFLY-1 is an open-label, pivotal Phase 2 trial. 3License agreement with Ipsen to commercialize OJEMDA (tovorafenib) outside the U.S. DAY301 is a license agreement with MabCare
Slide 16: Second Quarter 2024 Financial Performance
Second Quarter 2024 Financial Performance Charles York Chief Operating Officer and Chief Financial Officer
Slide 17: Second Quarter 2024 Financial Results
Second Quarter 2024 Financial Results All financial information is unaudited. 1 Includes stock-based compensation expense of $4.7 million and $9.4 million for the three and six months ended 6/30/24, and $3.4 million and $6.8 million for the three and six months ended 6/30/23, respectively. 2 Include
Slide 18: Thank You
Thank You Click to add text Nasdaq: DAWN
Day One Biopharmaceuticals — Q2 2024 Earnings Presentation on 6ix